insights_auto
Why is UCBJY up 2,55%?
Dive Deeperchevron_right
UCBJY:OTCMKTS
UCB Unsponsored Belgium ADR
USDÂ 115,47
arrow_upward
+2,55%(+2,87) 1D
15 Okt., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UCBJY...
Open
USDÂ 115,89
High
USDÂ 116,39
Low
USDÂ 115,15
Mkt. cap
39,72Â mjd
Avg. vol.
51,68Â k
Volume
74,77Â k
52-wk high
USDÂ 168,76
52-wk low
USDÂ 110,55
Beta
0,57
Shares outstanding
389,01Â m
No. of employees
9Â k
Open
USDÂ 115,89
High
USDÂ 116,39
Low
USDÂ 115,15
Mkt. cap
39,72Â mjd
Avg. vol.
51,68Â k
Volume
74,77Â k
52-wk high
USDÂ 168,76
52-wk low
USDÂ 110,55
Beta
0,57
Shares outstanding
389,01Â m
No. of employees
9Â k
News stories
From web sources and news partners
ad-hoc-news.de
·
22 uur gelede
UCB dedicates Georgia campus as UCB stock sits 29.15 percent below its high
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB Unsponsored Belgium ADR
CEOJean-Christophe Tellier
Employees9Â k
Founded18 Jan. 1928
Headquarters-
SectorPharmaceutical industry
Websiteucb.com